Gentian Diagnostics ASFRA:6FK +3.58%73 Pretax Margin % is 13.44% as of Jun. 2026. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued). Among 818 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 56.11% on this metric.
The historical rank and industry rank for Gentian Diagnostics AS's Pretax Margin % or its related term are showing as below:
FRA:6FK'
s Pretax Margin % Range Over the Past 10 Years
Min: -82.99 Med: -28.1 Max: 14.54
Current: -2.75
FRA:6FK's Pretax Margin % is ranked worse than 56.11% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs FRA:6FK: -2.75
Gentian Diagnostics AS (FRA:6FK) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Gentian Diagnostics AS Pretax Margin % Related Terms
Gentian Diagnostics AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6FK vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (FRA:6FK) has a Pretax Margin % of 13.44% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #459 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is Gentian Diagnostics AS's Pretax Margin % too high?
Gentian Diagnostics AS's current Pretax Margin % is 13.44%. The Medical Devices & Instruments industry median Pretax Margin % is 2.51. Gentian Diagnostics AS's value of 13.44% is 436.5% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #459 out of 818 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #459 out of 818 companies for Pretax Margin %. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Pretax Margin % is 2.51. Gentian Diagnostics AS's value of 13.44% is 436.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Pretax Margin % of 13.44% is 436.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Pretax Margin % is 13.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Pretax Margin % is 13.44% and 436.5% above the Medical Devices & Instruments industry median of 2.51. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Pretax Margin % is 13.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
Pretax Margin %: 13.44%
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
Industry Position: 436.5% above the Medical Devices & Instruments median (#459 of 818)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
